In the last trading session, 1.43 million InMed Pharmaceuticals Inc (NASDAQ:INM) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $0.45 changed hands at $0.05 or 13.43% during last session, the market valuation stood at $1.51M. INM’s last price was a discount, traded about -928.89% off its 52-week high of $4.63. The share price had its 52-week low at $0.36, which suggests the last value was 20.0% up since then. When we look at InMed Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.28 million shares, with the 3-month average coming to 1.71 million.
Analysts gave the InMed Pharmaceuticals Inc (INM) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended INM as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. InMed Pharmaceuticals Inc’s EPS for the current quarter is expected to be $iShares Russell 2000 ETF.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
InMed Pharmaceuticals Inc (NASDAQ:INM) trade information
Instantly INM was in green as seen at the end of in last trading. With action 16.20%, the performance over the past five days has been green. The jump to weekly highs of 0.5190 on Friday, 11/17/23 added 13.43% to the stock’s daily price. The company’s shares are showing year-to-date downside of -77.62%, with the 5-day performance at 16.20% in the green. However, in the 30-day time frame, InMed Pharmaceuticals Inc (NASDAQ:INM) is -24.67% down. Looking at the short shares, we see there were 18880.0 shares sold at short interest cover period of 0 days.
The consensus price target for the stock as assigned by Wall Street analysts is $20.00, meaning bulls need an upside of 97.75% from its current market value. According to analyst projections, INM’s forecast low is $20.00 with $20.00 as the target high. To hit the forecast high, the stock’s price needs a -4344.44% plunge from its current level, while the stock would need to soar -4344.44% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 39.17%.
INM Dividends
InMed Pharmaceuticals Inc is expected to release its next quarterly earnings report between November 09 and November 13.
InMed Pharmaceuticals Inc (NASDAQ:INM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.15% of InMed Pharmaceuticals Inc shares while 3.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.04%. There are 3.03% institutions holding the InMed Pharmaceuticals Inc stock share, with Susquehanna International Group, LLP the top institutional holder. As of Jun 29, 2023, the company held 0.41% of the shares, roughly 13672.0 INM shares worth $12667.0.
Bank of America Corporation holds the second largest percentage of outstanding shares, with 0.06% or 1834.0 shares worth $1699.0 as of Jun 29, 2023.
With 556.0 shares estimated at $745.0 under it, the former controlled 0.02% of total outstanding shares.
